BioNTech stated in a tweet, “During a time when Delta was the most common strain, our #mRNA vaccine provided 95.6 percent relative vaccine efficacy against #Covid19 after a booster shot. This is the first time efficacy data from a randomised, controlled vaccine booster trial has been published.”
According to the companies, a booster shot of the BioNTech/Pfizer vaccine is 95.6 percent effective against Covid-19 when compared to those who received two shots and a placebo.
They claimed that a trial of 10,000 people aged 16 and up showed 95.6 percent effectiveness against the diseases during a time when the Delta strain was prevalent.
The booster shot was also found to have a favourable safety profile, according to the study.
Pfizer claimed that the efficacy of its two-shot vaccine decreases over time, citing a study that found 84 percent effectiveness four months after a second dose, down from 96 percent at the start. Some countries had already made plans to administer booster doses.
BioNTech stated in a tweet, “During a time when Delta was the most common strain, our #mRNA vaccine provided 95.6 percent relative vaccine efficacy against #Covid19 after a booster shot. This is the first time efficacy data from a randomised, controlled vaccine booster trial has been published.”
“These findings provide additional evidence of the benefits of boosters as we strive to keep people well-protected against this disease,” said Pfizer CEO Albert Bourla in a statement.
The median age of the participants was 53 years, with 55.5 percent aged 16 to 55 years and 23.3 percent aged 65 or older.
